Genomic analysis of high-risk smoldering multiple myeloma

Haematologica

Volumn 97, Issue 9, 2012, Pages 1439-1443

  López Corral, Lucía ^a   Mateos, María Victoria ^a   Corchete, Luis A ^a   Sarasquete, María Eugenia ^a   de la Rubia, Javier ^b   de Arriba, Felipe ^c   Lahuerta, Juan José ^d   García Sanz, Ramón ^a   San Miguel, Jesús F ^a   Gutiérrez, Norma C ^a  

^a Centro de Investigacion del Cancer   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL MORALES MESEGUER   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

FISH; Gene expression profile; Smoldering myeloma; SNP array

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE; SYNDECAN 1; TUMOR MARKER;

ARTICLE; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SMOLDERING MULTIPLE MYELOMA; SNORD25 GENE; SNORD27 GENE; SNORD30 GENE; SNORD31 GENE; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONTROLLED STUDY; DNA MICROARRAY; FOLLOW UP; GENETICS; GENOMICS; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PLASMA CELL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE;

CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMA CELLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84865846727     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.060780     Document Type: Article

References (24)

1. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am. 2007;21(6):1093-113.
2. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582-90.
3. IMWG. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2010;121(5):749-57.
4. Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med. 1993;94(1):57-61.
5. Rajkumar SV. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Hematology Am Soc Hematol Educ Program. 2005;340-5.
6. Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20 (6):1625-34.
7. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96(6):2037-44.
8. Rosiñol L, Blade J, Esteve J, Aymerich M, Rozman M, Montoto S, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol. 2003;123(4):631-6.
9. Rosiñol L, Carrio A, Blade J, Queralt R, Aymerich M, Cibeira MT, et al. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol. 2005;13085):729-32.
10. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785-9.
11. Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586-92.
12. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J, et al. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I-a randomized study. Myeloma Group of Western Sweden. Eur J Haematol. 1993;50(2):95-102.
13. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15(8):1274-6.
14. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, et al. Thalidomide as initial therapy for earlystage myeloma. Leukemia. 2003;17(4):775-9.
15. Mateos MV, Lopez-Corral L, Hernandez MT, de la Rubia J, Lahuerta JJ, Giraldo P, et al. Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis. ASH Annual Meeting Abstracts 2009;114(22):614.
16. Mateos MV, Lopez-Corral L, Hernandez M, Giraldo P, de la Rubia J, de Arriba F, et al. Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment. ASH Annual Meeting Abstracts 2010;116 (21):1935.
17. Gutierrez NC, Castellanos MV, Martin ML, Mateos MV, Hernandez JM, Fernandez M, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia. 2006;21(1):143-50.
18. Lopez-Corral L, Gutierrez NC, Vidriales MB, Mateos MV, Rasillo A, Garcia-Sanz R, et al. The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells. Cancer Res. 2011;17(7):1692-700.
19. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121-7.
20. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113(22):5418-22.
21. Williams GT, Farzaneh F. Are snoRNAs and snoRNA host genes new players in cancer?. Nat Rev Cancer. 2012;12(2):84-8.
22. Mei YP, Liao JP, Shen J, Yu L, Liu BL, Liu L, et al. Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis. Oncogene. 2012;31(22): 2794-804.
23. Dong XY, Guo P, Boyd J, Sun X, Li Q, Zhou W, et al. Implication of snoRNA U50 in human breast cancer. J Genet Genomics. 2009;36(8):447-54.
24. Dong XY, Rodriguez C, Guo P, Sun X, Talbot JC, Zhou W, et al. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet. 2008;17(7):1031-42.